

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

---

**FORM SD**

---

**SPECIALIZED DISCLOSURE REPORT**

**GSK plc**  
(Exact name of Registrant as specified in its charter)

**England and Wales**  
(State or other jurisdiction  
of incorporation)

**001-15170**  
(Commission File Number)

**98-0607772**  
(I.R.S. Employer  
Identification No.)

**GSK plc**  
79 New Oxford Street  
London, WC1A 1DG  
United Kingdom  
(Address of principal executive offices)

**Victoria Whyte**  
**Company Secretary**  
**+44 20 8047 5000**  
(Name and telephone number of this person to contact in connection with this report)

Check the appropriate box to indicate the rule pursuant to which this form is being filed:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended \_\_\_\_\_.

---

## **Section 1 – Conflict Minerals Disclosure**

### **Item 1.01 Conflict Minerals Disclosure and Report**

Rule 13p-1 under the Securities Exchange Act of 1934, as amended, (the “Rule”) generally provides that a company must file a specialized disclosure report if it manufactures or contracts to manufacture products for which one or more of the following minerals are necessary to the functionality or production of the company’s products: cassiterite; columbite-tantalite (coltan); and wolframite; their derivatives tantalum, tin, and tungsten; and gold (collectively, “3TGs”). These are considered “conflict minerals” under the Rule regardless of their geographic origin and whether or not they fund armed conflict in the Democratic Republic of the Congo or its neighboring countries (the “covered countries”).

GSK is a global biopharma company which prevents and treats disease with specialty medicines, vaccines and general medicines. GSK focuses on science of the immune system and advanced technologies investing in four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases to significantly impact health at scale.

Pursuant to the Rule, we conducted in good faith a technical review of GSK’s products and surveyed our suppliers and contract manufacturing organizations (“CMOs”). This review and survey was updated via ongoing monitoring for calendar year 2024 to determine whether 3TGs were present in our products. For those products that did contain 3TGs, we conducted in good faith a reasonable country of origin inquiry that GSK believes was reasonably designed to determine whether any 3TG necessary to the functionality or production of these materials or products originated in the covered countries or was not from recycled or scrap sources. For any materials or products containing 3TGs, we requested information from the applicable suppliers and CMOs regarding the source of such 3TGs. None of the suppliers or CMOs indicated to us that any 3TGs contained in the materials or products they provided to GSK in 2024 came from the covered countries or were not from recycled or scrap sources.

In summary, as a result of our diligence on the suppliers and CMOs, we have no reason to believe that any of the 3TGs contained in our 2024 products that are within the scope of the Rule originated in the covered countries or were not from recycled or scrap sources.

The information in this Form SD is also publicly available on our website at [www.gsk.com/en-gb/company/codes-standards-and-reports/#conflict-minerals-report](http://www.gsk.com/en-gb/company/codes-standards-and-reports/#conflict-minerals-report).

### **Item 1.02 Exhibit**

Not applicable.

## **Section 2 – Resource Extraction Issuer Disclosure**

### **Item 2.01 Resource Extraction Issuer Disclosure and Report**

Not applicable.

## **Section 3 – Exhibits**

### **Item 3.01 Exhibits**

Not applicable.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Dated: May 30, 2025

/s/ Julie Brown  
Name: Julie Brown  
Title: Chief Financial Officer